Orthopedic surgery groups across the country are being bought up by private equity firms at a pace that is reshaping how musculoskeletal care gets delivered – and most patients have no idea it is happening.
The Quiet Consolidation Underway
For decades, orthopedic surgery operated as one of the last holdouts of independent specialty medicine. Groups of five, ten, sometimes twenty surgeons built their practices around long-term patient relationships, local hospital affiliations, and shared ownership structures that gave each physician a direct stake in the business. That model is now being systematically dismantled by private equity firms who have identified orthopedics as a high-margin, underconsolidated market ripe for rollup strategy.
The appeal is straightforward. Orthopedic procedures – joint replacements, spine surgeries, sports medicine interventions – carry strong reimbursement rates and generate consistent demand from an aging population. Unlike primary care, which PE-backed groups have also pursued aggressively, orthopedic practices often own ancillary revenue streams: ambulatory surgery centers, physical therapy wings, imaging suites, and durable medical equipment operations. When a PE firm acquires the physician group, it typically acquires those cash-generating assets alongside it.
The rollup model works by acquiring multiple regional groups under a single platform company, then standardizing administrative functions, renegotiating payer contracts from a position of greater market scale, and eventually seeking an exit – either through a sale to a larger platform, a strategic buyer, or in some cases a public offering. The individual surgeons who sell receive a combination of upfront cash and equity in the new platform, which means their financial upside is now tied to the performance of a portfolio of practices rather than just their own clinic.
This same pattern has played out in regional cardiology practices and dermatology before orthopedics caught PE’s full attention. The sequencing is not accidental. PE firms move through specialties methodically, targeting those with the right combination of fragmentation, procedure volume, and ancillary revenue potential. Orthopedics checks every box.
Why Surgeons Are Saying Yes
The decision to sell is rarely made under duress. For most orthopedic groups agreeing to these transactions, the motivations are a mix of financial calculation, exhaustion, and defensive positioning. Running an independent practice has grown meaningfully more complicated over the past fifteen years. Prior authorization requirements, billing complexity, electronic health record mandates, and rising malpractice costs have all added administrative weight that falls disproportionately on smaller groups without the staff to absorb it.
Physician burnout is a real factor in these decisions. A founding partner in a regional group who has spent thirty years building a practice may be looking at another decade of work before retirement – and a PE offer provides immediate liquidity at a valuation that independent sale to a junior partner simply cannot match. The rollup premium is real. PE firms can justify paying higher multiples on EBITDA because they are buying not just one practice but the option to integrate it into a larger platform worth considerably more at exit.
Younger surgeons within these groups often have complicated feelings about a sale. On one hand, they receive equity in the platform, which can appreciate substantially if the rollup succeeds. On the other, they lose the path to partnership ownership that defined how their predecessors built wealth. They are trading the chance to own their practice for the chance to own a slice of a financial product. Whether that trade is favorable depends almost entirely on execution and timing – two things no individual surgeon controls once the deal is signed.
Hospital systems, oddly, have accelerated this dynamic. As health systems have acquired physician groups aggressively over the past decade, independent orthopedic practices have found themselves squeezed on both sides – hospital employment removing their ability to recruit younger surgeons, and PE offering a third path that preserves some independence while providing the capital structure to compete. Many groups that sell to PE do so partly because they see hospital acquisition as the worse alternative.
The negotiation dynamics also favor quick decisions. PE firms typically approach groups with time-limited offers, sometimes framed as an opportunity to join a platform at an early stage before valuation multiples compress as the rollup matures. This creates pressure to decide without full visibility into how comparable deals have structured physician governance rights, compensation floors, or non-compete clauses. Groups that do not engage experienced healthcare transaction counsel before entering these processes consistently end up with worse deal terms.
What Changes After the Deal Closes
The immediate post-acquisition period at most PE-backed orthopedic groups looks relatively normal. Staff stays in place, the practice keeps its name, and the surgeons continue seeing patients under familiar conditions. The changes come gradually: productivity benchmarks that intensify over time, pressure to increase surgical volume at the affiliated ASC, reductions in administrative autonomy, and standardization of supply chains that removes some of the vendor relationships surgeons had built over careers. Clinical independence is rarely stripped away directly – it erodes at the edges through incentive structures that make certain choices more financially rewarding than others.
For patients, the most visible change is often scheduling and billing. Larger administrative platforms process insurance differently, and patients who have seen the same surgeon for years sometimes find that their insurance status or referral pathways have changed without explanation. Whether PE ownership ultimately affects clinical outcomes in orthopedics is a question the research has not yet settled cleanly – but the financial incentives built into these structures do not point toward restraint on procedure volume, and spine surgery in particular has a long history of overutilization even before private equity entered the conversation.
